Allouch C, Borderie V, Touzeau O, Scheer S, Nordmann J-P, Laroche L
Pôle Hospitalo-Universitaire Saint-Antoine, CHNO des Quinze-Vingts, Service d'Ophtalmologie, 28, rue de Charenton, 75012 Paris.
J Fr Ophtalmol. 2003 Jun;26(6):553-61.
To determine the incidence and factors influencing glaucoma following penetrating keratoplasty.
We prospectively studied 440 consecutive patients undergoing penetrating keratoplasty over a period of 5 years, with an average follow-up of 2 years. High intraocular pressure was defined as IOP over 20 mmHg measured by Goldmann applanation for at least 1 week or if a patient required topical treatment for at least 1 week. Before surgery, 18.7% of the patients presented with glaucoma or high intraocular pressure; 44.9% received a graft for a bullous keratopathy condition, 25.6% had keratoconus, 31.5% received an anterior chamber lens, and 48.5% were phakic.
After surgery, 42.2% of the patients had ocular pressure at 20 mmHg or more and required treatment for high ocular pressure. The increase in intraocular pressure appeared after an average delay of 3.3 +/- 4.7 months. The frequency of the increase in intraocular pressure was 54.3% for the bullous keratopathy patients, 26.6% for the keratoconus patients (p<0.001). At the end of the second year, the graft survival was 82.1% in absence of glaucoma, whereas it was 71.5% in cases of glaucoma after keratoplasty. Between all parameters that we studied, high intraocular pressure before surgery, etiology, the status, and receiver age over 60 years were the main factors influencing high intraocular pressure after keratoplasty. Intraocular pressure was correlated with the decrease in endothelial cell density and was at the origin of graft failure. Intraocular pressure correlated with the Best Spectacle Corrected Visual Acuity (BSCVA) by its effect on endothelial cell density and optic nerve destruction.
The increase in intraocular pressure is a real and serious complication of keratoplasty. Its physiopathology is very complex. Better knowledge of risk factors can be useful in controlling it.
确定穿透性角膜移植术后青光眼的发生率及影响因素。
我们前瞻性地研究了连续5年接受穿透性角膜移植术的440例患者,平均随访2年。高眼压定义为使用Goldmann压平眼压计测量眼压超过20 mmHg至少1周,或患者需要局部治疗至少1周。手术前,18.7%的患者患有青光眼或高眼压;44.9%的患者因大泡性角膜病变接受移植,25.6%的患者患有圆锥角膜,31.5%的患者植入了前房晶状体,48.5%的患者为有晶状体眼。
术后,42.2%的患者眼压达到或超过20 mmHg,需要接受高眼压治疗。眼压升高平均延迟3.3±4.7个月出现。大泡性角膜病变患者眼压升高的频率为54.3%,圆锥角膜患者为26.6%(p<0.001)。在第二年年底,无青光眼患者的植片存活率为82.1%,而穿透性角膜移植术后发生青光眼的患者为71.5%。在我们研究的所有参数中,术前高眼压、病因、状态以及60岁以上的接受者年龄是影响穿透性角膜移植术后高眼压的主要因素。眼压与内皮细胞密度降低相关,是植片失败的原因。眼压通过对内皮细胞密度和视神经破坏的影响与最佳矫正视力(BSCVA)相关。
眼压升高是角膜移植术真实且严重的并发症。其病理生理学非常复杂。更好地了解危险因素有助于控制该并发症。